Distinguished in Familial Dysautonomia

Dr. Stuart H. Isaacson

Stuart H. Isaacson, M.d, P.A.
Boca Raton, FL
Distinguished
in Familial Dysautonomia
Specialties:Neurology | Nephrology
Offers Telehealth
OverviewInsuranceLocationsClinical Research

Overview

Stuart Isaacson is a Neurologist and a Nephrologist in Boca Raton, Florida. Dr. Isaacson and is rated as a Distinguished provider by MediFind in the treatment of Familial Dysautonomia. His top areas of expertise are Parkinson's Disease, Drug Induced Dyskinesia, Orthostatic Hypotension, and Low Blood Pressure.

His clinical research consists of co-authoring 102 peer reviewed articles and participating in 20 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 13 articles and participated in 2 clinical trials in the study of Familial Dysautonomia.

Specialties
Neurology
Nephrology
Licenses
Psychiatry & Neurology in FL
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Locations

STUART H. ISAACSON, M.D, P.A.
951 Nw 13th St, 5e, Boca Raton, FL 33486
561-392-1818

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

19 Clinical Trials

A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 76-week Study Evaluating the Safety and Efficacy of Two Doses of Simufilam in Subjects With Mild-to-Moderate Alzheimer's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 76-week Study Evaluating the Safety and Efficacy of Two Doses of Simufilam in Subjects With Mild-to-Moderate Alzheimer's Disease
Enrollment Status: Terminated
Publish Date: February 05, 2025
Intervention Type: Drug
Study Drug: Simufilam
Study Phase: Phase 3
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Enrollment Status: Active_not_recruiting
Publish Date: January 24, 2025
Intervention Type: Drug
Study Drug: Donanemab
Study Phase: Phase 3
Rostock International Parkinson's Disease Study: an International, Multicenter, Epidemiological Observational Study
Rostock International Parkinson's Disease Study: an International, Multicenter, Epidemiological Observational Study
Enrollment Status: Active_not_recruiting
Publish Date: September 20, 2024
A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of CVN424 in Parkinson's Disease Patients With Motor Fluctuations
A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of CVN424 in Parkinson's Disease Patients With Motor Fluctuations
Enrollment Status: Completed
Publish Date: July 03, 2024
Intervention Type: Drug
Study Drug: CVN424
Study Phase: Phase 2
A Randomized, Placebo-Controlled, Double-Blind Study of ATH-1017 Treatment in Subjects With Parkinson's Disease Dementia or Dementia With Lewy Bodies
A Randomized, Placebo-Controlled, Double-Blind Study of ATH-1017 Treatment in Subjects With Parkinson's Disease Dementia or Dementia With Lewy Bodies
Enrollment Status: Completed
Publish Date: April 15, 2024
Intervention Type: Drug
Study Drug: ATH-1017
Study Phase: Phase 2
A Multicenter, Non-Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Orally Administered ENT-01 in Improving Constipation and Neurologic Symptoms in Patients With Parkinson's Disease and Constipation Over a 14-week Period
A Multicenter, Non-Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Orally Administered ENT-01 in Improving Constipation and Neurologic Symptoms in Patients With Parkinson's Disease and Constipation Over a 14-week Period
Enrollment Status: Terminated
Publish Date: March 19, 2024
Intervention Type: Drug
Study Drug: ENT-01
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate Safety, Tolerability and Efficacy of Orally Administered ENT-01 for the Treatment of Parkinson's Disease-Related Constipation (KARMET)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate Safety, Tolerability and Efficacy of Orally Administered ENT-01 for the Treatment of Parkinson's Disease-Related Constipation (KARMET)
Enrollment Status: Completed
Publish Date: February 20, 2024
Intervention Type: Drug
Study Drug: ENT-01
Study Phase: Phase 2
Cutaneous Phosphorlyated α-synuclein Detection as a Biomarker of Synucleinopathy
Cutaneous Phosphorlyated α-synuclein Detection as a Biomarker of Synucleinopathy
Enrollment Status: Completed
Publish Date: January 03, 2024
Intervention Type: Diagnostic test
A Multi-Center, Single-Dose, Multiple-Dose, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered ENT-01 for the Treatment of Parkinson's Disease Related Constipation
A Multi-Center, Single-Dose, Multiple-Dose, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered ENT-01 for the Treatment of Parkinson's Disease Related Constipation
Enrollment Status: Completed
Publish Date: December 27, 2023
Intervention Type: Other, Drug
Study Phase: Phase 1/Phase 2
The Parkinson's Progression Markers Initiative (PPMI)
The Parkinson's Progression Markers Initiative (PPMI)
Enrollment Status: Completed
Publish Date: November 14, 2023
Intervention Type: Drug
Study Drug: DaTscan
Study Phase: Phase 2
A Multicenter, Randomized, Active-controlled, Double-blind, Double-dummy, Parallel-group Clinical Trial, Investigating the Efficacy, Safety, and Tolerability of Continuous Subcutaneous ND0612 Infusion in Comparison to Oral IR-LD/CD in Subjects With Parkinson's Disease Experiencing Motor Fluctuations (BouNDless)
A Multicenter, Randomized, Active-controlled, Double-blind, Double-dummy, Parallel-group Clinical Trial, Investigating the Efficacy, Safety, and Tolerability of Continuous Subcutaneous ND0612 Infusion in Comparison to Oral IR-LD/CD in Subjects With Parkinson's Disease Experiencing Motor Fluctuations (BouNDless)
Enrollment Status: Active_not_recruiting
Publish Date: November 07, 2023
Intervention Type: Drug, Combination product
Study Drugs: ND0612 Solution, Carbidopa, Levodopa
Study Phase: Phase 3
RESTORE: A Clinical Study of Patients With Symptomatic Neurogenic Orthostatic Hypotension to Assess Sustained Effects of Droxidopa Therapy
RESTORE: A Clinical Study of Patients With Symptomatic Neurogenic Orthostatic Hypotension to Assess Sustained Effects of Droxidopa Therapy
Enrollment Status: Completed
Publish Date: August 23, 2023
Intervention Type: Drug
Study Drug: Droxidopa
Study Phase: Phase 4
A Phase 4, Open-Label, Efficacy and Safety Study of Apokyn® for Rapid and Reliable Improvement of Motor Symptoms in Parkinson Disease Subjects With Delayed Onset of L-Dopa Action
A Phase 4, Open-Label, Efficacy and Safety Study of Apokyn® for Rapid and Reliable Improvement of Motor Symptoms in Parkinson Disease Subjects With Delayed Onset of L-Dopa Action
Enrollment Status: Completed
Publish Date: August 14, 2023
Intervention Type: Drug
Study Phase: Phase 4
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of CX-8998 for Essential Tremor
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of CX-8998 for Essential Tremor
Enrollment Status: Completed
Publish Date: November 23, 2021
Intervention Type: Drug
Study Phase: Phase 2
Effect of LY3154207 on Cognition in Mild-to-Moderate Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)
Effect of LY3154207 on Cognition in Mild-to-Moderate Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)
Enrollment Status: Completed
Publish Date: July 23, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Clinico-Pathological Study of the Correspondence Between 18F-AV-1451 PET Imaging and Post-Mortem Assessment of Tau Pathology
A Clinico-Pathological Study of the Correspondence Between 18F-AV-1451 PET Imaging and Post-Mortem Assessment of Tau Pathology
Enrollment Status: Completed
Publish Date: September 07, 2020
Intervention Type: Drug, Procedure
Study Phase: Phase 3
A 4-Week, Double-blind, Placebo-controlled, Randomized, Multicenter, Crossover Study of the Safety, Efficacy, and Pharmacokinetics of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in Subjects With Parkinson's Disease and Excessive Sleepiness
A 4-Week, Double-blind, Placebo-controlled, Randomized, Multicenter, Crossover Study of the Safety, Efficacy, and Pharmacokinetics of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] in Subjects With Parkinson's Disease and Excessive Sleepiness
Enrollment Status: Completed
Publish Date: January 09, 2020
Intervention Type: Drug, Other
Study Phase: Phase 2
SYN120 a Dual 5-HT6/5-HT2A Antagonist Proof of Concept Study to Evaluate Its Safety, Tolerability and Efficacy in Parkinson's Disease Dementia (SYNAPSE)
SYN120 a Dual 5-HT6/5-HT2A Antagonist Proof of Concept Study to Evaluate Its Safety, Tolerability and Efficacy in Parkinson's Disease Dementia (SYNAPSE)
Enrollment Status: Completed
Publish Date: April 19, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 17 Less Clinical Trials

102 Total Publications

Corrigendum to "Recommendations for a paradigm shift in approach to increase the recognition and treatment of sialorrhea in Parkinson's disease" [Clin. Parkinsonism Related Dis. 9 (2023) 100223].
Corrigendum to "Recommendations for a paradigm shift in approach to increase the recognition and treatment of sialorrhea in Parkinson's disease" [Clin. Parkinsonism Related Dis. 9 (2023) 100223].
Journal: Clinical parkinsonism & related disorders
Published: July 16, 2024
Similar Doctors
Expertise in
7
conditions
Dr. Nestor Galvez-Jimenez
Neurology
Expertise in
7
conditions
Dr. Nestor Galvez-Jimenez
Neurology

Cleveland Clinic Florida (A Nonprofit Corporation)

2950 Cleveland Clinic Blvd, 
Weston, FL 
 (25.1 mi)
954-659-5000
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Nestor Galvez-Jimenez is a Neurologist in Weston, Florida. Dr. Galvez-Jimenez and is rated as a Distinguished provider by MediFind in the treatment of Familial Dysautonomia. His top areas of expertise are Primary Familial Brain Calcification, Familial Dysautonomia, Parkinson's Disease, and Burning Mouth Syndrome. Dr. Galvez-Jimenez is currently accepting new patients.

Expertise in
1
conditions
Dr. Jeffrey B. Gelblum
Neurology
Expertise in
1
conditions
Dr. Jeffrey B. Gelblum
Neurology

Neuroscience Consultants Llp

2801 Ne 213th St, Suite 1004, 
Aventura, FL 
 (26.9 mi)
305-936-9393
Languages Spoken:
English, French, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Jeffrey Gelblum is a Neurologist in Aventura, Florida. Dr. Gelblum and is rated as an Experienced provider by MediFind in the treatment of Familial Dysautonomia. His top areas of expertise are Irregular Sleep-Wake Syndrome, Tension Headache, Neuralgia, and Cerebellar Degeneration. Dr. Gelblum is currently accepting new patients.

Expertise in
2
conditions
Dr. Liza Smirnoff
Neurology
Expertise in
2
conditions
Dr. Liza Smirnoff
Neurology

University Of Miami

1150 Nw 14th St, 609 Pac, 
Miami, FL 
 (40.2 mi)
305-243-4900
Experience:
9+ years
Languages Spoken:
English, Russian, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Liza Smirnoff is a Neurologist in Miami, Florida. Dr. Smirnoff has been practicing medicine for over 9 years and is rated as an Experienced provider by MediFind in the treatment of Familial Dysautonomia. Her top areas of expertise are Migraine, Headache, Neuralgia, and Familial Dysautonomia. Dr. Smirnoff is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile